Earnings summaries and quarterly performance for REVIVA PHARMACEUTICALS HOLDINGS.
Executive leadership at REVIVA PHARMACEUTICALS HOLDINGS.
Board of directors at REVIVA PHARMACEUTICALS HOLDINGS.
Research analysts covering REVIVA PHARMACEUTICALS HOLDINGS.
Recent press releases and 8-K filings for RVPH.
Reviva Pharmaceuticals Holdings, Inc. Receives Nasdaq Listing Extension
RVPH
Delisting/Listing Issues
- On January 20, 2026, the Nasdaq Hearings Panel granted Reviva Pharmaceuticals Holdings, Inc. (RVPH) an exception to the $1.00 Minimum Bid Price requirement for continued listing.
- The company is required to demonstrate compliance with the Bid Price Requirement by March 27, 2026.
- This exception follows an initial non-compliance notice received on May 13, 2025, and a subsequent delisting threat on November 11, 2025, after the initial compliance period expired.
- RVPH intends to take definitive steps to regain compliance, including potentially implementing a reverse stock split if necessary.
- Failure to regain and maintain compliance could lead to delisting, which would negatively impact the common stock's price, liquidity, and the company's ability to access capital markets.
Jan 23, 2026, 9:15 PM
Reviva Pharmaceuticals Announces FDA Recommendation for Additional Phase 3 Study for Brilaroxazine
RVPH
New Projects/Investments
Guidance Update
- Reviva Pharmaceuticals' lead molecule, brilaroxazine, for schizophrenia, has demonstrated strong efficacy and a good safety profile in completed trials involving approximately 900 patients.
- Following a pre-NDA meeting, the FDA recommended an additional Phase 3 study for brilaroxazine to fulfill the requirements for filing a New Drug Application (NDA) for schizophrenia.
- The company anticipates initiating the new Phase 3 study in early Q2 and completing it by mid-2027, with an expected NDA submission in Q4 2027.
- Reviva Pharmaceuticals currently holds over $12 million in cash and needs to raise at least $50 million to fund the additional study and NDA submission.
Jan 15, 2026, 6:00 PM
Reviva Pharmaceuticals Discusses Brilaroxazine Clinical Data and FDA NDA Requirements
RVPH
New Projects/Investments
Guidance Update
- Reviva Pharmaceuticals (RVPH) presented positive clinical trial data for its lead drug, Brilaroxazine, for schizophrenia, highlighting its strong efficacy in both acute and long-term treatment, including for negative symptoms, and a favorable safety profile.
- Following a pre-NDA meeting last month, the FDA recommended an additional Phase 3 study for Brilaroxazine to fulfill NDA filing requirements for schizophrenia.
- The company plans to initiate the new Phase 3 study in early Q2 (2026) and complete it by mid-2027, with an anticipated NDA submission in Q4 2027.
- Reviva currently has over $12 million in cash and needs to raise at least $50 million to fund the additional study and NDA submission.
Jan 15, 2026, 6:00 PM
Reviva Pharmaceuticals Provides Update on Brilaroxazine Development and FDA Pathway
RVPH
New Projects/Investments
Guidance Update
- Reviva Pharmaceuticals (RVPH) is developing Brilaroxazine for schizophrenia, having completed multiple trials with approximately 900 patients.
- Clinical data for Brilaroxazine showed strong efficacy in treating schizophrenia, including negative symptoms, and a favorable safety profile with low relapse rates over one year.
- Following a pre-NDA meeting, the FDA recommended an additional Phase 3 study for Brilaroxazine to meet NDA filing requirements for schizophrenia.
- The company anticipates initiating the new Phase 3 study in early Q2 (2026), completing it by mid-2027, and submitting the NDA in Q4 2027.
- Reviva currently has over $12 million in cash and plans to raise at least $50 million to fund the additional study and NDA submission.
Jan 15, 2026, 6:00 PM
Reviva Announces Publication on Clinical Vocal Biomarker Data from RECOVER Phase 3 Trial
RVPH
New Projects/Investments
- Reviva Pharmaceuticals Holdings announced the publication of an article in Biological Psychiatry detailing clinical vocal biomarker data from its RECOVER Phase 3 clinical trial for brilaroxazine in schizophrenia.
- The findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia, supporting clinician-assessed efficacy outcomes.
- The publication also highlights the potential of speech latency as an objective biomarker and enrichment tool, which could reduce sample size and enhance outcomes in future schizophrenia clinical trials.
- Brilaroxazine, an in-house discovered new chemical entity, previously showed positive topline data from the global Phase 3 RECOVER trial, meeting all primary and secondary endpoints.
Jan 8, 2026, 1:00 PM
RVPH Reports Q3 2025 Financial Results and Provides Business Updates
RVPH
Earnings
New Projects/Investments
Guidance Update
- Reviva Pharmaceuticals Holdings, Inc. reported a net loss of $4.0 million, or $0.06 per share, for the three months ended September 30, 2025, an improvement compared to a net loss of $8.4 million, or $0.25 per share, for the same period in 2024.
- As of September 30, 2025, the company's cash and cash equivalents totaled approximately $13.2 million.
- A pre-NDA meeting with the FDA to discuss brilaroxazine's path to approval for schizophrenia is planned for Q4 2025, with a potential NDA submission targeted for Q2 2026.
- The company also announced the granting of a European patent covering the use of brilaroxazine for the treatment of pulmonary fibrosis, successfully completed the Phase 3 RECOVER open-label extension 1-year study for schizophrenia, and raised $9.0 million in gross proceeds from a public equity offering.
Nov 13, 2025, 9:19 PM
Reviva Pharmaceuticals Holdings Announces European Patent Grant for Brilaroxazine in Pulmonary Fibrosis
RVPH
New Projects/Investments
- Reviva Pharmaceuticals Holdings announced that the European Patent Office (EPO) granted European Patent 3749324, covering the use of brilaroxazine for treating pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF).
- This patent strengthens the company's intellectual property portfolio, adding to existing protection for brilaroxazine in key markets such as the United States, China, and Japan.
- Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in pulmonary fibrosis and has received Orphan Drug Designation from the U.S. FDA for both IPF and pulmonary arterial hypertension (PAH).
- The company plans to expand brilaroxazine's clinical development from schizophrenia into additional high-value indications, leveraging its well-tolerated profile observed in trials.
Nov 10, 2025, 1:00 PM
Revival Pharmaceuticals Discusses Biloroxazine Clinical Progress and Regulatory Strategy
RVPH
New Projects/Investments
Guidance Update
- Revival Pharmaceuticals (RVPH) is a late-stage biopharma company focused on developing Biloroxazine for schizophrenia, currently in Phase 3 development, with potential for other neuropsychiatric conditions.
- Clinical trials involving over 900 patients have demonstrated Biloroxazine's robust efficacy, particularly for negative symptoms, and durable efficacy with a low relapse rate. The Phase 3 RECOVER one study showed a 10 separation from placebo in PANSS total score.
- The drug exhibits a favorable safety profile, with hardly any motor side effects (less than 1% in Phase 3) and a low discontinuation rate of 35% in the open-label study, compared to 50-80% for other antipsychotics.
- Revival Pharmaceuticals anticipates a Type C meeting with the FDA in December 2025 (Q4 2025) to discuss pre-NDA feedback, with a potential for early NDA filing in Q2 2026 and drug approval in early 2027.
Sep 30, 2025, 2:15 PM
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of Public Offering
RVPH
- Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced the pricing of a public offering on September 18, 2025, for aggregate gross proceeds of approximately $9 million.
- The offering includes 27,000,000 shares of common stock (or equivalents) along with Series E and Series F warrants to purchase up to 27,000,000 shares each, at a combined offering price of $0.335 per share and accompanying warrants.
- Both Series E and Series F warrants have an exercise price of $0.335 per share; Series E warrants expire in five years, and Series F warrants expire in 12 months from the issuance date.
- The closing of the offering is expected around September 22, 2025, with net proceeds of approximately $8.1 million intended for research and development activities, working capital, and general corporate purposes.
Sep 19, 2025, 9:27 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more